Risk-Predictive and Diagnostic Biomarkers for Colorectal Cancer; a Systematic Review of Studies Using Pre-Diagnostic Blood Samples Collected in Prospective Cohorts and Screening Settings.
Risk-Predictive and Diagnostic Biomarkers for Colorectal Cancer; a Systematic Review of Studies Using Pre-Diagnostic Blood Samples Collected in Prospective Cohorts and Screening Settings.
复制标题
DOI：
10.3390/cancers13174406
复制
发表时间：
2021-08-31
期刊：
影响因子：
5.2
通讯作者：
Van Guelpen B
中科院分区：
文献类型：
--
作者：
Harlid S;Gunter MJ;Van Guelpen B
目前，结直肠癌筛查通常涉及粪便检测，但血液检测可能更容易被筛查参与者接受。大多数关于结直肠癌血液生物标志物的研究都是使用患者样本进行的，可能无法预测早期癌症或癌前肿瘤。这篇系统性综述总结了使用症状发作前收集的样本进行研究的证据。这些研究的质量通常很高，但很少有潜在的生物标志物在多项研究中显示出一致的临床相关结果。其中，抗p53抗体是最有希望的标记物。生物标志物组的表现优于单一标志物。本综述的结果强调了在独立的诊断前环境中验证有前途的结直肠癌生物标志物的必要性。这篇系统性综述总结了在诊断前、无症状环境中进行的研究中血液为基础的结直肠癌生物标志物的证据。在最初确定的1372项研究中，最终选择包括30项前瞻性队列研究和23项一般筛选研究。总体而言，研究具有高质量，但在数据分析和结果呈现方面存在相当大的差异，并且很少有生物标志物表现出临床相关的区分能力。最有希望的生物标志物之一是抗p53抗体，在一个筛查队列和两个前瞻性队列研究中诊断前3-4年的结果一致。蛋白质是评估的最常见类型的生物标志物，特别是癌胚抗原（CEA）和C-反应蛋白（CRP），结果一般。其他潜在的有希望的生物标志物包括蛋白质，如AREG，MIC-1/GDF 15，LRG 1和FGF-21，代谢物和/或代谢物谱，非编码RNA和DNA甲基化，以及重新设计的常规实验室测试，如铁蛋白和葡萄糖-葡萄糖指数。生物标志物组通常比单一标志物实现更高的区分性能。总之，本系统性综述强调抗p53抗体作为一种有前途的血液生物标志物，与其他特异性蛋白一起用于结直肠癌筛查。它还强调了在独立的诊断前环境中验证有前途的生物标志物的必要性。
Currently, colorectal cancer screening typically involves stool tests, but a blood test might be more acceptable for screening participants. Most research on blood biomarkers for colorectal cancer has been conducted using samples from patients and may not be as predictive for early-stage cancer or pre-cancerous tumors. This systematic review summarizes the evidence from studies that used samples collected before the onset of symptoms. The quality of the studies was generally high, but very few potential biomarkers showed consistent, clinically relevant results across more than one study. Of these, the anti-p53 antibody was the most promising marker. Panels of biomarkers performed better than single markers. The results of this review underscore the need for validation of promising colorectal cancer biomarkers in independent pre-diagnostic settings. This systematic review summarizes the evidence for blood-based colorectal cancer biomarkers from studies conducted in pre-diagnostic, asymptomatic settings. Of 1372 studies initially identified, the final selection included 30 studies from prospective cohorts and 23 studies from general screening settings. Overall, the investigations had high quality but considerable variability in data analysis and presentation of results, and few biomarkers demonstrated a clinically relevant discriminatory ability. One of the most promising biomarkers was the anti-p53 antibody, with consistent findings in one screening cohort and in the 3–4 years prior to diagnosis in two prospective cohort studies. Proteins were the most common type of biomarker assessed, particularly carcinoembryonic antigen (CEA) and C-reactive protein (CRP), with modest results. Other potentially promising biomarkers included proteins, such as AREG, MIC-1/GDF15, LRG1 and FGF-21, metabolites and/or metabolite profiles, non-coding RNAs and DNA methylation, as well as re-purposed routine lab tests, such as ferritin and the triglyceride–glucose index. Biomarker panels generally achieved higher discriminatory performance than single markers. In conclusion, this systematic review highlighted anti-p53 antibodies as a promising blood-based biomarker for use in colorectal cancer screening panels, together with other specific proteins. It also underscores the need for validation of promising biomarkers in independent pre-diagnostic settings.
登录
查看更多内容
影响因子：
--
作者：
De Chiara, Loretta;Paez de la Cadena, Maria;Cordero, Oscar J.
通讯作者：
Cordero, Oscar J.
影响因子：
24.5
作者：
de Klerk, C. M.;Gupta, S.;Essink-Bot, M. L.
通讯作者：
Essink-Bot, M. L.
影响因子：
4.6
作者：
Doherty M;Theodoratou E;Walsh I;Adamczyk B;Stöckmann H;Agakov F;Timofeeva M;Trbojević-Akmačić I;Vučković F;Duffy F;McManus CA;Farrington SM;Dunlop MG;Perola M;Lauc G;Campbell H;Rudd PM
通讯作者：
Rudd PM
影响因子：
24.5
作者：
Church TR;Wandell M;Lofton-Day C;Mongin SJ;Burger M;Payne SR;Castaños-Vélez E;Blumenstein BA;Rösch T;Osborn N;Snover D;Day RW;Ransohoff DF;PRESEPT Clinical Study Steering Committee, Investigators and Study Team
通讯作者：
PRESEPT Clinical Study Steering Committee, Investigators and Study Team
Stard 2015：用于报告诊断准确性研究的基本项目的更新列表。
DOI：
10.1136/bmj.h5527
发表时间：
2015-10-28
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Bossuyt PM;Reitsma JB;Bruns DE;Gatsonis CA;Glasziou PP;Irwig L;Lijmer JG;Moher D;Rennie D;de Vet HC;Kressel HY;Rifai N;Golub RM;Altman DG;Hooft L;Korevaar DA;Cohen JF;STARD Group
通讯作者：
STARD Group